A New Era in Functional Genomics Using CRISPR/Cas9 Knockout Screening
Received Date: Mar 23, 2018 / Accepted Date: Apr 05, 2018 / Published Date: Apr 09, 2018
In this commentary, we discussed the new exciting progress in CRISPR based screening technology field and highlight recent developments in the area of CRISPR-based functional genomics. High-throughput functional genomics using CRISPR-Cas9 revolutionized our ability to decipher cellular function in health and disease. Despite its limitations, the simplicity and effectiveness of CRISPR/Cas9 based screening, makes an enormous impact on genomic screening and thus scientific discovery.
Keywords: Genome-editing; CRISPR based screening; Genetic screening
Genetic screening has been a powerful tool to identify gene function, in particular through studying cellular phenotypes arising from genome-wide perturbations. The main method for genomewide loss-of-function screening is using short hairpin (sh) RNA or siRNA libraries in order to knock down mRNA transcript levels. More recently developed techniques utilizing Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome editing have significantly improved gain- or loss-of-function studies. It is now possible to make much more precise changes to endogenous genes and completely knock out their expression in vitro and in vivo [1-3]. As a powerful genetic tool, CRISPR/Cas9 has been used to study and potentially treat single gene disorders (e.g. sickle cell anemia and β- thalassemia), cardiovascular diseases (e.g. coronary heart disease due to higher LDL cholesterol levels) and HIV infection (e.g. inactivating HIV co-receptors CCR5 and CXCR4) [4,5].
In 2014, two seminal publications in Science first demonstrated that CRISPR/Cas9 system can be used as a screening tool for genetic studies [6,7]. They developed genome-scale lentiviral pooled libraries targeting approximately 17,000 and 18,000 human genes (with 5 -6 gRNAs/gene), respectively. Both positive and negative selection screening was successfully carried out with CRISPR pooled library in mammalian cells. Importantly, the CRISPR based screening was demonstrated superior to an shRNA screening because of its ability to knock out the genes efficiently. We have recently taken advantage of the genome-scale CRISPR-Cas9 knockout (GeCKO) library developed by the Broad Institute to study the mechanisms underlying FLT3 inhibitor resistance in acute myeloid leukemia (AML) . In our screen, we identified SPRY3, an intracellular inhibitor of FGF signaling, and GSK3, a canonical Wnt signaling antagonist, and demonstrated that re-activation of downstream FGF/Ras/ERK and Wnt signaling as major mechanisms of resistance to the FLT3 inhibitor. In the last four years, numerous CRISPR based pooled genetic screens were performed to study various biological or pathological processes, uncovered mediators of drug resistance, pathogen toxicity, tumor growth/metastasis as well as defined cell-essential genes of the human genome and new roadblocks in reprogramming mouse embryonic fibroblasts etc. A genome-wide CRISPR screen in a mouse model of tumor growth and metastasis was conducted by transducing a CRISPR library into a non-small-cell lung cancer cell line and transplanted cells subcutaneously into immunocompromised mice . Enriched single guide RNAs (sgRNAs) in lung metastases and late stage primary tumors were identified to target a small set of genes, suggesting specific loss-of-function mutations drive tumor growth and metastasis. A similar approach was used to identify tumor suppressor mechanisms of hepatocellular carcinoma as well as new immunotherapy targets [10,11]. More recently, Chow et al. delivered an adeno-associated virus (AAV)-mediated CRISPR library directly into the mouse brain that conditionally expressed Cas9 through stereotaxic injection to identify functional suppressors in glioblastoma .
Conventional pooled CRISPR screenings are limited to analyses of cell-population behavior during the screening process. This limitation was recently overcome through the combination of CRISPR screen with single-cell RNA-seq. The studies described CROP-seq , Perturb-seq [14,15], and CRISPR-seq , CRISPR-UMI  use the CRISPR-Cas9 system to create up to thousands of genetic perturbations in parallel within a single sample, as with conventional pooled screens. But by using single-cell RNA-seq as readout, the approaches enable the gene knockout and phenotype of each cell to be examined simultaneously. These new methods have already been proved to be a powerful tool to study cellular signaling including the T-cell receptor signaling pathway in Jurkat cells, and mammalian unfolded protein response, the transcriptional program in the bone marrow-derived dendritic cells (BMDC) response to lipopolysaccharide (LPS), mouse embryonic fibroblasts reprogramming as well as regulatory circuits of innate immunity.
Although CRISPR based screening has been reported to perform better with low noise, minimal off-target effects and experimental consistency, compared to knock down approaches using CRISPRi and shRNA , the application of the approach has its own limitations. The Cas9/gRNA does not always lead to knockout as the indels could be in-frame mutations, thereby keeping the gene function intact. Additionally, several studies have shown that the correlation between cellular lethality and the number of DNA double strand breaks (DSBs) in a cell, independent of the gene being targeted. Thus, CRISPR knockout based screens can identify false-positive hits for highly amplified genomic regions, including non-expressed genes [19,20].
Representations of the in vitro and in vivo screenings up to date are summarized in Table 1. Taken together, high-throughput functional genomics using CRISPR-Cas9 revolutionized our ability to decipher cellular function in health and disease. Despite its limitations, the simplicity and effectiveness of CRISPR/Cas9 based screening, promise many exciting new applications in the coming years.
|In vitro||Representative study reference||Cas9 Protein||gRNAlibrary||Cells||Methods||Scientific Implications|
|Wang, et al. 2014, Science||Dox-inducible WTcas9||7,114 genes, 73,151 gRNAs||Human leukemia cell lines (KBM7 and HL60)||Positive and negative selection||Established CRISPR/Cas9 screens as a powerful tool for systematic genetic analysis in mammalian cells|
|Shalem, et al. 2014, Science||ConstituitiveWTcas9||Human GeCKO||Human melanoma cell line (A375) andstem cell line (HUES62)||Positive and negative selection||Demonstrated feasisbility and advantages of CRISPR/Cas9 system for pooled genome-scale functional screening|
|Hou, et al. 2017, Cancer Res||ConstituitiveWTcas9||Human GeCKO||Human leukemia cell line (MV4-11)||Positive selection||Identification of genes whose loss confer resistance to drug in AML|
|Zhou, et al. 2014, Science||WTcas9||291 genes, 869 gRNAs||Human cervical carcinoma cell line (Hela)||Positive selection||Identification of genes essential for cell intoxication|
|Park, et al. 2016, Nature Genetics||WTcas9||18,543 genes, 187,536 gRNAs||Human CD4+ T cell line (CCRF-CEM)||Positive selection||Identification of host genes important in facililtating virus infection|
|Hart, et al. 2015, Cell||WTcas9||90K, TKO library||Human colorectal carcinoma cell line (HCT116), colorectal carcinoma cell line (DLD1), glioblastoma cell line (GBM), immortalized retinal epithelial cell line (RPE1), melanoma cell line (A375)||negative selection||Expansion of the catalog of human cell line fitness genes and identification of genetic vulnerabilities and therapeutic targets|
|Tzelepis, et al. 2016, Cell Reports||WTcas9||18,010 genes, 90,709 gRNAs||Human AML cell lines (MOLM-13, MV4-11, HL-60, OCI-AML2, OCI-AML3)||negative selection||Identification of genetic vulnerabilities and therapeutic targets|
|Arroyo, et al. 2016, Cell Metabolism||WTcas9||18,335 genes, 74,687 gRNAs||Human CML cell line (K562)||Death screening||Genetic analysis using dead cells|
|In vivo||Chen, et al. 2015, Cell||WTcas9||Mouse GeCKO||Mouse lung cancer cell line (KPD)||Mutated cells were subcutaneously injected into immunocompromised Nu/Nu mice||Providing a road map for in vivo screening|
|Song, et al. 2017, Gastroenterology||WTcas9||Mouse GeCKO||Mouse embryonic liver progenitor cell||Mutated cells were subcutaneously injected into immunocompromised Nu/Nu mice||In vivoCRISPR-based genetic screening in tumor models|
|Manguso, et al. 2017, Nature||WTcas9||Mouse TSG||Mouse melanoma cell line (B16)||Mutated cells were subcutaneously injected into mice treated with immunotherapy||In vivoCRISPR-based genetic screening in tumor models|
|Chow, et al. 2017, Nat Neurosci||Conditional WTcas9 expression||56 genes, 288 gRNAs||Mouse primary astrocyte||Mutated cells were sterotaxically injected into the mice brain||In vivoCRISPR-based genetic screening in tumor models|
|Single-Cell CRISPR Screening||Dixit, et al. 2016, Cell||WTcas9||24 transcription factors (67 gRNAs)||Mouse bone marrow derived dendritic cells||Cells were stimulated with LPS in 7 days after infection||Dissecting the transcriptional program in the BMDC response to LPS|
|WTcas9||10 transcription factors (46 gRNAs)||Human CML cell line (K562) stably expressing Cas9||Cells were stimulated with LPS in 7 days after infection||Global transcriptional modules predict individual TF functions|
|Adamson, et al. 2016, Cell||dCas9||9 three-guide vectors, 91 sgRNAs||Human CML cell line (K562) stably expressing dCas9-KRAB||Treatment of 4mg/mL tunicamycin for 6 hrs||Revealing bifurcated UPR within a population and allows unbiased discovery of UPR-controlled genes|
|Jaitin, et al. 2016, Cell||WTcas9-GFP||57 gRNAs targeting 22 genes||CD11c+ myeloid cells sorted from Cas9-GFP transgenic mice||Cells were treated with lipopolysaccharide (LPS)||Rewiring of regulatory circuits in myeloid cells|
|A pool of Cebpb, Irf8, Rela, Stat1, Stat2 and two control gRNAs||Mouse CD11c+ myeloid cells sorted from Cas9-GFP transgenic mice||Cells were treated with LPS after 7 days following transplantation||Uncovering the complexity of myeloid regulatory circuits in immune niches in vivo|
|Datlinger, et al. 2017, Nat Methods||WTcas9||TCR-related 87 gRNAs (29 genes)||Human T-ALL cell line (jurkat) stably expressing Cas9||T-cell -receptor induction||Facilitating large screens by providing a vector that makes the guide RNA itself readable|
|Non-targeting 20 gRNAs|
|Essential 9 gRNAs|
|Michils, et al. 2017, Nat Methods||Dox-inducible Cas9||26,514 guides targeting 6,560 genes||Mouse embryonic fibroblasts (MEFs)||Positive selection screen||Identifying new roadblocks of cellular reprogramming|
|Note: Dox: Doxycycline; GeCKO: Genome-scale CRISPR-Cas9knockOut library; sgRNA: Single guide RNA; LPS: Lipopolysaccharide|
Table 1: Representative CRISPR based screenings In vitro and In vivo and combined with single cell RNA-seq.
- Jinek M, Chylinski K, Fonfara I, Hauer M, DoudnaJA, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-821.
- DoudnaJA, Charpentier E (2014) Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346: 1258096.
- Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157: 1262-1278.
- Maeder ML, Gersbach CA (2016) Genome-editing technologies for gene and cell therapy. MolTher 24: 430-446.
- Motta BM, PramstallerPP, Hicks AA, Rossini A (2017) The impact of CRISPR/Cas9 technology on cardiac research: from disease modelling to therapeutic approaches. Stem Cells Int 2017: 8960236.
- Wang T, Wei JJ, Sabatini DM, Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343: 80-84.
- Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, et al. (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343: 84-87.
- Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, et al. (2017) A genome-wide crispr screen identifies genes critical for resistance to FLT3 inhibitor AC220. Cancer Res 77: 4402-4413.
- Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, et al. (2015) Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160: 1246-1260.
- Song CQ, Li Y, Mou H, Moore J, Park A, et al. (2017) Genome-wide CRISPR screen identifies regulators of mitogen-activated protein kinase as suppressors of liver tumors in mice. Gastroenterol 152: 1161-1173.
- MangusoRT, Pope HW, Zimmer MD, Brown FD, Yates KB, et al. (2017) In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547: 413-418.
- Chow RD, Guzman CD, Wang G, Schmidt F, Youngblood MW, et al. (2017) AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci 20: 1329-1341.
- Datlinger P, Rendeiro AF, Schmidl C, Krausgruber T, Traxler P, et al. (2017) Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods 14: 297-301.
- Adamson B, Norman TM, Jost M, Cho MY, Nunez JK, et al. (2016) A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167: 1867-1882.
- Dixit A, Parnas O, Li B, Chen J, FulcoCP, et al. (2016) Perturb-Seq: Dissecting molecular circuits with scalable single-cell rna profiling of pooled genetic screens. Cell 167: 1853-1866.
- Jaitin DA, Weiner A, Yofe I, Lara-Astiaso D, Keren-Shaul H, et al. (2016) Dissecting immune circuits by linking crispr-pooled screens with Single-Cell RNA-Seq. Cell 167: 1883-1896.
- Michlits G, Hubmann M, Wu SH, Vainorius G, Budusan E, et al. (2017) CRISPR-UMI: Single-cell lineage tracing of pooled CRISPR-Cas9 screens. Nat Methods 14: 1191-1197.
- Evers B, Jastrzebski K, Heijmans JP, Grernrum W, BeijersbergenRL, et al. (2016) CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol 34: 631-633.
- Munoz DM, CassianiPJ, Li L, Billy E, KornJM, et al. (2016) CRISPRscreens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highlyamplified genomic regions. Cancer Discov 6: 900-913.
- Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, et al. (2016) Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov 6: 914-929.
Citation: Cai W, Li W, Yang D, Xie H, Huang J (2018) A New Era in Functional Genomics Using CRISPR/Cas9 Knockout Screening. J Mol Genet Med 12: 345 DOI: 10.4172/1747-0862.1000345
Copyright: © 2018 Cai W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Select your language of interest to view the total content in your interested language
Share This Article
March 19-20, 2020 Dubai, UAE
April 08-09,2020 Sydney, Australia
May 25-26, 2020 Rome, Italy
May 29-30, 2020 London, UK
- Total views: 2981
- [From(publication date): 0-2018 - Jan 26, 2020]
- Breakdown by view type
- HTML page views: 2895
- PDF downloads: 86